$17.09
-0.09(-0.50%)
Mkt Cap $1.1B
$3.70
$25.31
52-Week Range
At a Glance
AI-generatedMonte Rosa Therapeutics reported collaboration revenue of $123.7 million for FY 2025, up 63% YoY from $75.6 million in 2024, driven by progress under Roche and Novartis agreements, including $150 million upfront from Novartis for VAV1 MGDs and $120 million from the 2025 Novartis deal.
$1.1B
Market Cap
$123M
Revenue
-$38M
Net Income
Employees142
Fundamentals
How The Business Makes Money
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001826457
ISINUS61225M1027
CUSIP61225M102
Phone617 949 2643
Address645 Summer Street, Boston, MA, 02210, US
SEC EDGAR